Information Library
Results for: Late Phase
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Understanding the Complexity of HTA Networks
Presentation — November 27, 2011
As stakeholders’ influence shifts, demonstrating value is imperative for the success of every pharmaceutical product. Learn more about Quintiles HTA Watch service. -
Quintiles Strengthens Late Phase Offerings with Acquisition of Outcome Sciences, Inc.
Press Release — October 19, 2011 – With late phase (Phase IIIB and Phase IV) research becoming increasingly important to multiple healthcare stakeholders, Quintiles has acquired Outcome Sciences, Inc. (Outcome).
-
Quintiles Names New Global Head of Clinical & Data Operations
Press Release — October 6, 2011 – Quintiles announced that Steven Skolsky has been appointed Global Head of its Clinical & Data Operations (CDO) unit.
-
Quintiles Approach to "Real-World" Research helps Biopharma Customers Drive Competitive Advantage
Press Release — September 19, 2011 –A perfect storm of stakeholder demands, unprecedented data access, new data channels and technologies is driving a dramatic shift in research methodologies among biopharmaceutical companies, according to a new report from Quintiles.
-
How Informative is Your Segmentation?
Hear from the Experts — September 15, 2011
Article published by Quintiles' Pieter Sheth-Voss in the Winter 2010 issue of Market Research magazine was recently awarded the David K. Hardin Memorial Award for 2011. -
Methods Matter
White Paper — July 18, 2011
As healthcare decision making becomes more complex, stakeholders are demanding real-world evidence tailored to their own individual needs. -
A Focus on CNS
Brochure — July 1, 2011
Quintiles is your ally for broad and deep CNS expertise in every aspect of the drug development process. -
KoNECT & Quintiles Partner to Advance Clinical Research
Press Release — May 30, 2011 – The Korea National Enterprise for Clinical Trials (KoNECT) and Quintiles have partnered to produce educational events in South Korea for investigators and biopharmaceutical companies.
-
Quintiles Joins the I-SPY 2 Breast Cancer Trial
Hear from the Experts — April 14, 2011
The I-SPY 2 clinical trial involves 800 patients with advanced breast cancer, and employs innovative adaptive trial design and genetic and biological markers from individual patients’ tumors to screen multiple investigational therapies simultaneously. -
Leveraging social networks to conduct observational research
Presentation — March 26, 2011
Quintiles’ presentation describes the benefits of social networks in terms of patient identification, cost and time, relative to traditional observational research approaches.
